Key hire
Non-executive Director, Aravax
Dr Brett Haumann
Roles
| Role | Organisation | Sources |
|---|---|---|
| Vice President of Clinical Development (former) | GlaxoSmithKline | Brandon BioCatalyst portfolio, Brandon Capital portfolio |
| Non-executive Director | Aravax | Brandon BioCatalyst portfolio, Brandon Capital portfolio |
| Head of the R&D Committee (former) | Aimmune Therapeutics | Brandon BioCatalyst portfolio, Brandon Capital portfolio |
| Chief Medical Officer and Senior Vice President of Development (former) | Theravance Biopharma | Brandon BioCatalyst portfolio, Brandon Capital portfolio |
Coverage
Stories naming Dr Brett Haumann. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Key hire
Aravax appoints Dr Brett Haumann to Board of Directors
Clinical-stage biotech Aravax has added pharma veteran Dr Brett Haumann, formerly of ReViral, Theravance, GSK and Aimmune, as a non-executive director ahead of a Phase 2 study of its peanut allergy therapy PVX108.